Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study
Ikusi/ Ireki
Data
2017-12-22Egilea
Ferreira, Isabel
Croca, Sara
Raimondo, Maria Gabriella
Matharu, Manjit
Miller, Sarah
Giles, Ian
Isenberg, David
Ioannou, Yiannis
Hanly, John G.
Urowitz, Murray B.
Anderson, Nicole
Aranow, Cynthia
Askanase, Anca
Bae, Sang-Cheol
Bernatsky, Sasha
Bruce, Ian N.
Buyon, Jill
Clarke, Ann E.
Dooley, Mary Anne
Fortin, Paul R.
Ginzler, Ellen
Gladman, Dafna
Gordon, Caroline
Inanc, Murat
Jacobsen, Soren
Kalunian, Kenneth
Kamen, Diane
Khamashta, Munther
Lim, Sam
Manzi, Susan
Merrill, Joan
Nived, Ola
Peschken, Christine
Petri, Michelle
Ramsey Goldman, Rosalind
Ruiz Irastorza, Guillermo
Sanchez-Guerrero, Jorge
Steinson, Kristjan
Sturfelt, Gunnar K.
Van Vollenhoven, Ronald
Wallace, Daniel J.
Zoma, Asad
Rahman, Anisur
Arthritis Research & Therapy 19 : (2017) // Article ID 287
Laburpena
Background: In patients with systemic lupus erythematosus (SLE) there is no serological test that will reliably distinguish neuropsychiatric (NP) events due to active SLE from those due to other causes. Previously we showed that serum levels of nitrated nucleosomes (NN) were elevated in a small number of patients with NPSLE. Here we measured serum NN in samples from a larger population of patients with SLE and NP events to see whether elevated serum NN could be a marker for NPSLE.
Methods: We obtained serum samples from patients in the Systemic Lupus International Collaborative Clinics (SLICC) inception cohort. This included 216 patients with NP events and two matched controls with SLE but no NP events for each of these patients. For the NP patients we tested samples taken before, during and after the NP event.
Results: Twenty-six patients had events attributed to SLE according to the most stringent SLICC attribution rule. In these patients there was no association between onset of event and elevated serum NN. In 190 patients in whom events were not attributed to SLE by the SLICC rules, median serum NN was elevated at the onset of event (P = 0.006). The predominant clinical features in this group of 190 patients were headache, mood disorders and anxiety.
Conclusions: Serum NN levels rise at the time of an NP event in a proportion of patients with SLE. Further studies are needed to determine the value of serum NN as a biomarker for NPSLE.